Ligand reports Q3 EPS $1.84, consensus $1.35

Reports Q3 revenue $51.81M, consensus $40.65M.”We just had one of the best quarters of performance in the history of Ligand (LGND). This success is due to the ongoing strength of our growing portfolio of commercial-stage programs, and we are pleased to announce an increase in guidance for the second time this year,” said Todd Davis, CEO of Ligand. “This quarter, we had several key portfolio events, including the successful commercial launches of Ohtuvayre(TM) and CAPVAXIVE(TM). as well as the full FDA approval of FILSPARI(R). We believe each of these products, along with our recently acquired QARZIBA(R), will be key drivers of revenue growth for Ligand in the coming years.”